Delaware Chapter of the American College of CardiologyOur purpose is to contribute to the prevention of cardiovascular diseases, to ensure optimal quality of care for individuals with such diseases, and to foster the highest professional ethical standards. Please let us know what information you want to see here. Feel free to contact us with your ideas, needs and comments. |
|
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Latest in Cardiology from ACC.org
- Did Disparities in ICD Implantations Worsen During the COVID-19 Pandemic? | NCDR StudyThe incidence of ICD implantations declined significantly during the COVID-19 pandemic, according to a recent study published in Heart Rhythm. Although disparities by sex, race and ethnicity persisted during peak COVID, they did not worsen.
- AFib Ablation Approaches Differ by Hospital Teaching Status | NCDR StudyProcedural approaches for atrial fibrillation (AFib) ablation differ by hospital teaching status; however, overall complication rates are similar, according to a recent study published in JAHA.
- ACC CardiaCast: The Evolving Role of PCSK9 Inhibitors in LDL-C ManagementIn this episode of CardiaCast, Dr. Michael Blaha will be joined by Dr. Ann Marie Navar to discuss the 2026 updates to ACC/AHA guideline on management of dyslipidemia and key clinical trial data supporting the use of PCSK9 inhibitors in getting patients to their lipid goals.
- Clinical Obesity Emerges as Independent Risk Factor For New-Onset HF, MortalityA cohort study published May 4 in JACC: Asia identified clinical obesity as a risk factor for new-onset heart failure (HF) and all-cause mortality, largely due to related clinical conditions and excess weight. Treating clinical obesity as an independent disease may increase the effectiveness of HF prevention strategies.
- ALLEPRE: Nurse-Coordinated Prevention Program May Reduce Long-Term CV RiskImplementing a nurse-coordinated prevention program (NCPP) significantly reduced long-term major adverse cardiovascular events (MACE) and improved body weight control, physical activity and pharmacotherapy adherence in post-hospitalization patients with acute coronary syndrome (ACS), according to results from the ALLEPRE trial published May 5 in EHJ.



